Inter occasion variability in individual optimal design
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605533849 | ||
| 003 | CHVBK | ||
| 005 | 20210128100840.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10928-015-9449-6 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10928-015-9449-6 | ||
| 245 | 0 | 0 | |a Inter occasion variability in individual optimal design |h [Elektronische Daten] |c [Anders Kristoffersson, Lena Friberg, Joakim Nyberg] |
| 520 | 3 | |a Inter occasion variability (IOV) is of importance to consider in the development of a design where individual pharmacokinetic or pharmacodynamic parameters are of interest. IOV may adversely affect the precision of maximum a posteriori (MAP) estimated individual parameters, yet the influence of inclusion of IOV in optimal design for estimation of individual parameters has not been investigated. In this work two methods of including IOV in the maximum a posteriori Fisher information matrix (FIMMAP) are evaluated: (i) MAPocc—the IOV is included as a fixed effect deviation per occasion and individual, and (ii) POPocc—the IOV is included as an occasion random effect. Sparse sampling schedules were designed for two test models and compared to a scenario where IOV is ignored, either by omitting known IOV (Omit) or by mimicking a situation where unknown IOV has inflated the IIV (Inflate). Accounting for IOV in the FIMMAP markedly affected the designs compared to ignoring IOV and, as evaluated by stochastic simulation and estimation, resulted in superior precision in the individual parameters. In addition MAPocc and POPocc accurately predicted precision and shrinkage. For the investigated designs, the MAPocc method was on average slightly superior to POPocc and was less computationally intensive. | |
| 540 | |a The Author(s), 2015 | ||
| 690 | 7 | |a Inter occasion variability (IOV) |2 nationallicence | |
| 690 | 7 | |a Optimal design (OD) |2 nationallicence | |
| 690 | 7 | |a Maximum a posteriori (MAP) |2 nationallicence | |
| 690 | 7 | |a Fisher information |2 nationallicence | |
| 690 | 7 | |a Bayesian |2 nationallicence | |
| 690 | 7 | |a Pharmacometrics |2 nationallicence | |
| 690 | 7 | |a Shrinkage |2 nationallicence | |
| 700 | 1 | |a Kristoffersson |D Anders |u Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 75124, Uppsala, Sweden |4 aut | |
| 700 | 1 | |a Friberg |D Lena |u Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 75124, Uppsala, Sweden |4 aut | |
| 700 | 1 | |a Nyberg |D Joakim |u Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 75124, Uppsala, Sweden |4 aut | |
| 773 | 0 | |t Journal of Pharmacokinetics and Pharmacodynamics |d Springer US; http://www.springer-ny.com |g 42/6(2015-12-01), 735-750 |x 1567-567X |q 42:6<735 |1 2015 |2 42 |o 10928 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10928-015-9449-6 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10928-015-9449-6 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kristoffersson |D Anders |u Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 75124, Uppsala, Sweden |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Friberg |D Lena |u Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 75124, Uppsala, Sweden |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nyberg |D Joakim |u Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 75124, Uppsala, Sweden |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Journal of Pharmacokinetics and Pharmacodynamics |d Springer US; http://www.springer-ny.com |g 42/6(2015-12-01), 735-750 |x 1567-567X |q 42:6<735 |1 2015 |2 42 |o 10928 | ||